LET’S MAKE A WORLD OF DIFFERENCE

Discover how we help biotech partners move oncology programs forward faster — combining deep therapeutic expertise, rapid startup, and data-driven insights to enable smarter decisions from first-in-human through registration.

  • Proven performance across complex oncology indications
  • Faster study startup and enrollment through strong site relationships
  • Deep oncology expertise paired with a flexible, biotech-focused approach
Let’s talk about your oncology program

PROVEN RESULTS IN ONCOLOGY

We don’t just support oncology trials — we help sponsors overcome critical development challenges.

CASE STUDY:

Accelerating a First-in-Human Oncology Study

A clinical-stage biotech company faced delays in its Phase I/II first-in-human oncology study, putting a key First Site Initiated (FSI) milestone at risk. Worldwide rapidly mobilized to accelerate startup and restore program momentum.

RESULTS:

  • Accelerated startup timelines through rapid mobilization and parallel execution
  • Achieved FSI ahead of target, exceeding the sponsor’s goal
  • Delivered FSI within 12 weeks of kickoff and 9 weeks from regulatory submission
  • Helped maintain momentum tied to a critical funding milestone

Delivering measurable impact where it matters most: speed, execution, and milestone-driven success.

SPEAK DIRECTLY WITH OUR ONCOLOGY EXPERTS

Connect with the team leading complex oncology trial strategy and execution, bringing deep expertise and real-world insight at every stage.

Keya Watkins, PMP

President, Oncology

30 years of experience in drug development and oncology CRO operations across biopharma and clinical research organizations.

Panteli Theocharous, PhD, FRCPath

Chief Therapeutics & Clinical Strategy Officer and President of Europe

Biotech leader with 35+ years’ experience, advancing therapies, driving innovation, commercialization, and growth.

Andrew Zupnick, PhD

Vice President, Oncology Drug Development

25+ years focused exclusively on oncology, leading drug development, study optimization, operational oversight, and innovation initiatives.

Rogeria Moreira, MD, PhD, MBA

Vice President, Medical Affairs, Oncology

25+ years of oncology and hematology experience across clinical development, medical affairs, and regulatory leadership roles.

Gijsbert Veerman

Vice President, Early Phase Oncology, Europe

30+ years in clinical research with expertise in early phase oncology, advancing innovative cancer therapies and clinical strategy.

Get practical guidance on how to move your oncology program forward with confidence.

Talk to our oncology experts